{"log_id": 8132266593815766784, "direction": 0, "words_result_num": 58, "words_result": [{"probability": {"variance": 0.00154, "average": 0.969036, "min": 0.901648}, "location": {"width": 86, "top": 170, "height": 25, "left": 221}, "words": "毒理研究"}, {"probability": {"variance": 0.010932, "average": 0.949307, "min": 0.527577}, "location": {"width": 786, "top": 180, "height": 47, "left": 221}, "words": "动物毒性:本品小鼠、大鼠、犬给药剂量分别为3ng/kg/L、4mg/kg1l和2mg/kg/日(分"}, {"probability": {"variance": 0.007538, "average": 0.979355, "min": 0.436239}, "location": {"width": 826, "top": 208, "height": 47, "left": 181}, "words": "别相当于临床最大推荐剂量的5,22和2倍)时,均发现心脏增大,形态学检查可见心室"}, {"probability": {"variance": 3.3e-05, "average": 0.997116, "min": 0.978042}, "location": {"width": 458, "top": 245, "height": 38, "left": 182}, "words": "肥大,这可能与血容量增加导致心脏负荷加大有关"}, {"probability": {"variance": 2.2e-05, "average": 0.997865, "min": 0.978836}, "location": {"width": 787, "top": 263, "height": 47, "left": 222}, "words": "遗传毒性:体外细菌基因致突变试验、体外人淋巴细胞染色体畸变试验、小鼠体内微核"}, {"probability": {"variance": 5.8e-05, "average": 0.996212, "min": 0.961001}, "location": {"width": 803, "top": 292, "height": 47, "left": 183}, "words": "试验、体内、外大鼠程序外DNA合成试验(UDS)结果均为阴性。小鼠淋巴瘤体外试验中"}, {"probability": {"variance": 0.012772, "average": 0.972991, "min": 0.432431}, "location": {"width": 476, "top": 328, "height": 37, "left": 184}, "words": "在代谢活化条件下可见突变率有轻度增加约2倍)。"}, {"probability": {"variance": 0.004112, "average": 0.97802, "min": 0.680807}, "location": {"width": 790, "top": 346, "height": 47, "left": 223}, "words": "生殖毒性:本品剂量达40mg/kg/日(相当于人日服最大推荐剂量下ALC的116倍),对"}, {"probability": {"variance": 0.004403, "average": 0.983336, "min": 0.578099}, "location": {"width": 826, "top": 375, "height": 47, "left": 184}, "words": "雄性大鼠交配和生育力无影响。本晶可改变雌性大鼠的动情周期(剂量2mg/kg/日,相当于"}, {"probability": {"variance": 0.003401, "average": 0.974463, "min": 0.760298}, "location": {"width": 829, "top": 404, "height": 47, "left": 184}, "words": "人口服最大推荐剂量下AC的20倍),降低雌性大鼠的生育力(40mg/kg/L,相当于人口服"}, {"probability": {"variance": 0.006561, "average": 0.977075, "min": 0.547546}, "location": {"width": 828, "top": 432, "height": 46, "left": 184}, "words": "最大推荐剂量下AUC的200倍),并伴中的孕激素和雌激素降低。在0.2mg/kg/日(相当"}, {"probability": {"variance": 0.004207, "average": 0.982113, "min": 0.5924}, "location": {"width": 812, "top": 459, "height": 48, "left": 184}, "words": "于人日服最大推荐剂量下AUC的3倍)剂量下,未见到上述改变。本品剂量为0.6和4"}, {"probability": {"variance": 0.009304, "average": 0.976197, "min": 0.373345}, "location": {"width": 826, "top": 487, "height": 47, "left": 186}, "words": "mg/kg/(相当于人口服最大推荐剂量下AC的3和15倍),可降低猴子卵泡期血清雌二醇"}, {"probability": {"variance": 0.003936, "average": 0.985697, "min": 0.596246}, "location": {"width": 829, "top": 517, "height": 43, "left": 185}, "words": "水平,继而使黄体激素水平和黄体期孕剩水平下降,并出现闭经,这可能与本品直接抑制卵"}, {"probability": {"variance": 0.023266, "average": 0.934772, "min": 0.376204}, "location": {"width": 829, "top": 544, "height": 44, "left": 185}, "words": "巢甾体激素的生成有关。大鼠怀孕早期给予本留,对着床或胚胎无影;但在妊娠中、晚期"}, {"probability": {"variance": 0.022659, "average": 0.911158, "min": 0.411768}, "location": {"width": 828, "top": 571, "height": 44, "left": 185}, "words": "给予本品,可引起大鼠和家免胚胎死亡和生长延滞。大鼠和家免给药剂量分别达3g/kg/L"}, {"probability": {"variance": 0.005037, "average": 0.964768, "min": 0.638425}, "location": {"width": 818, "top": 599, "height": 44, "left": 188}, "words": "和100mg/kg/日(分别相当于人口服最大推荐剂量下AUC的20和75倍)时,未见致畸作用"}, {"probability": {"variance": 0.010367, "average": 0.967896, "min": 0.505636}, "location": {"width": 826, "top": 624, "height": 46, "left": 188}, "words": "大鼠给药3mg/kg/L时可使胎盘出现病理改变。大鼠妊娠和哺乳期连续给药可引起窝仔数减"}, {"probability": {"variance": 0.000291, "average": 0.994721, "min": 0.892293}, "location": {"width": 813, "top": 652, "height": 44, "left": 187}, "words": "少,新生鼠生存能力下降和出生后生长迟缓,但生长迟缓可于青春期后恢复。本品对大鼠"}, {"probability": {"variance": 8.9e-05, "average": 0.994825, "min": 0.957905}, "location": {"width": 567, "top": 684, "height": 40, "left": 187}, "words": "家兔胎盘、胚胎/胎仔和仔代的无影响剂量分别为0.2mg/kg/日"}, {"probability": {"variance": 0.027007, "average": 0.944964, "min": 0.377555}, "location": {"width": 211, "top": 680, "height": 30, "left": 804}, "words": "g/kg/日,约为人日服"}, {"probability": {"variance": 0.01198, "average": 0.960303, "min": 0.579961}, "location": {"width": 829, "top": 705, "height": 46, "left": 186}, "words": "最大推荐剂量下AC的4倍。尚无充分和严格控制的孕妇临床研究资料只有当其在利益"}, {"probability": {"variance": 0.003906, "average": 0.98442, "min": 0.608202}, "location": {"width": 828, "top": 732, "height": 46, "left": 188}, "words": "大于对胎儿的潜在危险性时,孕妇才可以服用本品。大鼠乳汁中检测到了罗格对酮的相关物"}, {"probability": {"variance": 0.019214, "average": 0.936836, "min": 0.416196}, "location": {"width": 827, "top": 756, "height": 53, "left": 189}, "words": "质,但本品是否经人乳汁分泌尚不清楚。由于许多药物可经人乳汁泌;,哺乳妇女不宜使"}, {"probability": {"variance": 0.00827, "average": 0.965572, "min": 0.602899}, "location": {"width": 827, "top": 784, "height": 51, "left": 190}, "words": "用本品。现有资料明显提示,妊娠期间血糖水平异常可增加新生儿先天性畸形的发生率、新"}, {"probability": {"variance": 0.024176, "average": 0.93736, "min": 0.376449}, "location": {"width": 816, "top": 815, "height": 43, "left": 191}, "words": "生儿的发病率和死亡率,为此大多数专家建议在妊娠期单用胰岛以尽可能维持正掌的"}, {"probability": {"variance": 1e-06, "average": 0.99842, "min": 0.996968}, "location": {"width": 62, "top": 860, "height": 23, "left": 189}, "words": "糖水平"}, {"probability": {"variance": 0, "average": 0.726352, "min": 0.726352}, "location": {"width": 19, "top": 851, "height": 20, "left": 944}, "words": "A"}, {"probability": {"variance": 0.002985, "average": 0.974544, "min": 0.756962}, "location": {"width": 566, "top": 874, "height": 39, "left": 229}, "words": "致癌性:小鼠掺食给予本品2年,剂量为0.4、1.5和6mg/kg"}, {"probability": {"variance": 0.004526, "average": 0.947373, "min": 0.798939}, "location": {"width": 169, "top": 870, "height": 29, "left": 847}, "words": "高剂量相当于人日"}, {"probability": {"variance": 0.022983, "average": 0.929766, "min": 0.355061}, "location": {"width": 830, "top": 901, "height": 44, "left": 189}, "words": "服最大推荐剂量下AC的12倍):末见致癌作用,但在1.5mg/kg/上剂量,可引起脂"}, {"probability": {"variance": 0.005382, "average": 0.964046, "min": 0.585297}, "location": {"width": 828, "top": 932, "height": 45, "left": 189}, "words": "肪组织增生。大鼠经口给予本品年,剂量为0.05、0.3和2mg/kg/日高剂分别相当于"}, {"probability": {"variance": 0.021082, "average": 0.926763, "min": 0.476308}, "location": {"width": 828, "top": 965, "height": 43, "left": 191}, "words": "人口服最大推荐剂量下AUC的10(雄性)倍租20倍(雌性)],在0.3mg/kg/和更高剂最"}, {"probability": {"variance": 0.001069, "average": 0.990384, "min": 0.79785}, "location": {"width": 824, "top": 994, "height": 47, "left": 194}, "words": "下,可明显增加大鼠良性脂肪组织瘤的发生率。上述两种动物上发现的增生反应与本品对脂"}, {"probability": {"variance": 3e-05, "average": 0.99649, "min": 0.978634}, "location": {"width": 310, "top": 1038, "height": 34, "left": 194}, "words": "肪组织过度而持久的药理作用有关"}, {"probability": {"variance": 2e-06, "average": 0.998954, "min": 0.996112}, "location": {"width": 135, "top": 1074, "height": 27, "left": 196}, "words": "【药代动力学】"}, {"probability": {"variance": 0.001362, "average": 0.988909, "min": 0.799052}, "location": {"width": 598, "top": 1090, "height": 41, "left": 234}, "words": "据国外文献资料报道,在治疗剂量范围内,罗格列酮的血浆峰浓度"}, {"probability": {"variance": 4.4e-05, "average": 0.992036, "min": 0.979949}, "location": {"width": 102, "top": 1089, "height": 27, "left": 914}, "words": "与药时曲线"}, {"probability": {"variance": 0.005027, "average": 0.970519, "min": 0.71187}, "location": {"width": 734, "top": 1114, "height": 46, "left": 194}, "words": "下面积(AUC)随剂量增加而成比例增加,消除半衰期为3-4小时,与剂量无关"}, {"probability": {"variance": 0.000303, "average": 0.991691, "min": 0.930719}, "location": {"width": 596, "top": 1146, "height": 38, "left": 233}, "words": "吸收:罗格列酮的绝对生物利用度为99%。血药浓度达峰时间("}, {"probability": {"variance": 0.054371, "average": 0.791051, "min": 0.438918}, "location": {"width": 196, "top": 1106, "height": 72, "left": 890}, "words": "为1小时"}, {"probability": {"variance": 0.001738, "average": 0.988315, "min": 0.826926}, "location": {"width": 314, "top": 1180, "height": 33, "left": 192}, "words": "食不改变本品的AUC值,但可引起"}, {"probability": {"variance": 1e-06, "average": 0.99902, "min": 0.997213}, "location": {"width": 120, "top": 1178, "height": 23, "left": 559}, "words": "下降约28%及"}, {"probability": {"variance": 8e-06, "average": 0.998434, "min": 0.988565}, "location": {"width": 290, "top": 1168, "height": 34, "left": 731}, "words": "延迟至1.75小时,此改变无明"}, {"probability": {"variance": 0.006385, "average": 0.981532, "min": 0.615416}, "location": {"width": 454, "top": 1204, "height": 35, "left": 194}, "words": "显临床意义,故罗格列酮在空腹或进餐时服用均可"}, {"probability": {"variance": 0.00987, "average": 0.960105, "min": 0.576966}, "location": {"width": 785, "top": 1222, "height": 45, "left": 235}, "words": "分布:群体药代动力学表明,罗格列酮的平均口服分布容积(VssF)大约为17.6升(±"}, {"probability": {"variance": 0.001863, "average": 0.986257, "min": 0.755868}, "location": {"width": 554, "top": 1256, "height": 40, "left": 195}, "words": "30%)。约99.8%的罗格列酮与血浆蛋白(主要是白蛋白)结合"}, {"probability": {"variance": 0.00853, "average": 0.978604, "min": 0.43648}, "location": {"width": 787, "top": 1278, "height": 44, "left": 235}, "words": "代谢:罗格列可被完全代谢,无形药物从尿中排出,其主要代谢途径为N一脱甲基"}, {"probability": {"variance": 0.000112, "average": 0.994022, "min": 0.960369}, "location": {"width": 291, "top": 1318, "height": 34, "left": 194}, "words": "和羟化后与硫酸和葡萄糖醛酸结"}, {"probability": {"variance": 0.010494, "average": 0.956093, "min": 0.55954}, "location": {"width": 481, "top": 1308, "height": 35, "left": 538}, "words": "于在街环中所有代谢产物的活性均明显弱于原形化合"}, {"probability": {"variance": 0.003632, "average": 0.973204, "min": 0.779372}, "location": {"width": 270, "top": 1347, "height": 33, "left": 195}, "words": "物,故对胰岛素增敏作用甚微"}, {"probability": {"variance": 0.001298, "average": 0.980215, "min": 0.83972}, "location": {"width": 785, "top": 1363, "height": 42, "left": 237}, "words": "体外研究表明,罗格列酮主要经P450同功酶CYP2C8代谢,经CYP2C9代谢仅占很小部"}, {"probability": {"variance": 0, "average": 0.999896, "min": 0.999896}, "location": {"width": 21, "top": 1410, "height": 23, "left": 196}, "words": "分"}, {"probability": {"variance": 0.015369, "average": 0.948835, "min": 0.480536}, "location": {"width": 787, "top": 1417, "height": 42, "left": 235}, "words": "排泄:口服或静脉给予{C}马装酸罗格列酮后,约64%从尿中排出,约23%从粪使中"}, {"probability": {"variance": 0.025082, "average": 0.915724, "min": 0.493623}, "location": {"width": 500, "top": 1450, "height": 37, "left": 213}, "words": "出,{“C)相关物质的血浆半衰期范围为103-158小时"}, {"probability": {"variance": 1.2e-05, "average": 0.997489, "min": 0.987845}, "location": {"width": 289, "top": 1481, "height": 33, "left": 232}, "words": "2型糖尿病患者群体药代动力学"}, {"probability": {"variance": 0.003304, "average": 0.984021, "min": 0.627998}, "location": {"width": 785, "top": 1496, "height": 46, "left": 238}, "words": "共642名男性和405名女性2型糖尿病患者(年龄35-80岁)参加了3项大样本的临"}, {"probability": {"variance": 0.00254, "average": 0.985363, "min": 0.697805}, "location": {"width": 828, "top": 1525, "height": 44, "left": 195}, "words": "床实验,其群体药代动力学结果表明,马来酸罗格列酮药代动力学参数不受年龄、种族、吸"}], "language": 3}